

Contents

List of contributors	ix
Preface	xi
1 Molecular Mechanisms of Glucocorticoid Receptor Action	1
<i>Pankaj Bhavsar and Ian M. Adcock</i>	
1.1 Introduction	1
1.2 Glucocorticoid receptor	2
1.3 Gene induction by GR	2
1.4 GR transactivation and histone acetylation	3
1.5 Post-translational modifications of GR	5
1.6 Repression of NF- κ B-induced inflammatory gene expression by GR-NF- κ B	6
1.7 GR-NF- κ B cross-talk	7
1.8 Role of HDAC2 in glucocorticoid function	8
1.9 Overexpression of HDAC2 restores glucocorticoid sensitivity in alveolar macrophages	9
1.10 Acetylation of hsp90 and regulation of GR function	10
1.11 Other mechanisms of GR action	10
1.12 Conclusions	12
2 Side Effects of Topical and Oral Glucocorticoids	19
<i>Heike Schäcke, Khusru Asadullah and Wolf-Dietrich Döcke</i>	
2.1 Introduction	19
2.2 Glucocorticoid-induced side effects	21
2.3 Summary	33
3 Glucocorticoid Receptor Subtypes and Steroid Sensitivity	39
<i>Robert H. Oakley and John A. Cidlowski</i>	
3.1 Introduction	39
3.2 Overview of classic GR function	40
3.3 GR subtypes arising from alternative splicing	43
3.4 GR subtypes arising from alternative translation initiation	47
3.5 Conclusions	49
4 Dissociated Glucocorticoids	55
<i>Ian M. Adcock</i>	
4.1 Introduction	55

4.2	Asthma and chronic obstructive pulmonary disease are chronic inflammatory diseases of the airways	55
4.3	Regulation of inflammatory gene expression	56
4.4	Effects on inflammation	57
4.5	Mechanisms of glucocorticoid action	58
4.6	Dissociated glucocorticoids	60
4.7	GR cross-talk with other nuclear receptors and coactivators	62
4.8	Overcoming steroid insensitivity	64
4.9	Glucocorticoid-sparing approaches to anti-inflammatory therapy	65
4.10	Conclusion	66
5	Generalized Glucocorticoid Insensitivity: Clinical Phenotype and Molecular Mechanisms	73
	<i>Evangelia Charmandari, Tomoshige Kino and George P. Chrousos</i>	
5.1	Introduction	73
5.2	Molecular mechanisms of glucocorticoid resistance	75
5.3	Conclusions	85
6	Corticosteroid Responsiveness in Asthma: Clinical Aspects	89
	<i>Kian Fan Chung</i>	
6.1	Introduction	89
6.2	Effects of corticosteroids in asthma	89
6.3	Definition of corticosteroid insensitivity	90
6.4	Oral CS responsiveness in asthma	91
6.5	ICS responsiveness in asthma	94
6.6	CS responsiveness in severe asthma	97
6.7	Surrogates for CS responsiveness in asthma	99
6.8	Pharmacokinetics of systemic CS in severe asthma	100
6.9	CS responsiveness in cigarette smokers and chronic obstructive pulmonary disease	101
6.10	Other diseases of CS insensitivity	102
6.11	Conclusions	102
7	Glucocorticoid-insensitive Asthma: Molecular Mechanisms	109
	<i>John W. Bloom</i>	
7.1	Introduction	109
7.2	GR abnormalities	110
7.3	GR nuclear translocation	112
7.4	Cross-talk with transcription factors	115
7.5	NF- κ B, GR, histones and chromatin remodelling	116
7.6	Epigenetics and asthma	119
7.7	Conclusions	120
8	Cigarette Smoke, Oxidative Stress and Corticosteroid Responsiveness	125
	<i>Irfan Rahman and David Adenuga</i>	
8.1	Oxidative stress	125
8.2	Cigarette smoke/oxidative stress-induced NF- κ B-mediated pro-inflammatory gene expression	127

8.3	Histone acetylation and deacetylation	129
8.4	Corticosteroids	129
8.5	Histone deacetylases	133
8.6	Reversing Glucocorticoids / Corticosteroid resistance	138
8.7	Conclusion	141
9	Regulation of Glucocorticoid Sensitivity by Macrophage Migration Inhibitory Factor	145
	<i>Eric F. Morand</i>	
9.1	Introduction	145
9.2	MIF as a pro-inflammatory factor	145
9.3	Relationship between MIF and glucocorticoids	151
9.4	Conclusions	155
10	Steroid-sparing Strategies: Long-acting Inhaled β_2-Agonists	163
	<i>Anna Miller-Larsson and Olof Selroos</i>	
10.1	Introduction	163
10.2	Why and when is a steroid-sparing effect of LABA important in asthma?	163
10.3	Effects of lower dose ICS/LABA versus a higher dose ICS on lung function, symptoms and use of reliever medication	164
10.4	Effects of lower dose ICS/LABA versus higher dose ICS on exacerbations	165
10.5	Protocols with tapering ICS doses with and without LABA while maintaining asthma control	166
10.6	Reducing ICS doses using an adjustable ICS/LABA dosing regimen	167
10.7	Reducing ICS doses using Symbicort® maintenance and reliever therapy	168
10.8	Does enhanced anti-inflammatory efficacy explain steroid-sparing effects in ICS/LABA therapy?	170
10.9	Possible Mechanisms of Steroid-sparing Effects by Addition of LABA to ICS	175
11	Steroid-sparing Strategies: Other Combinations	187
	<i>Gaetano Caramori, Kazuhiro Ito and Alberto Papi</i>	
11.1	Introduction	187
11.2	Theophylline as steroid-sparing treatment in asthma and COPD	187
11.3	Selective inhibitors of PDE4	190
11.4	Modulators of the synthesis or action of key inflammatory mediators	193
11.5	Anticholinergics	193
11.6	Leukotriene synthesis inhibitors and leukotriene receptor antagonists	195
11.7	Anti-IgE therapy	198
11.8	Macrolides/ketolides	199
11.9	TNF α inhibitors	200
11.10	Conclusions	202
12	Kinases as Anti-inflammatory Targets for Respiratory Disease	207
	<i>Iain Kilty</i>	
12.1	Introduction	207
12.2	Pharmacological targeting of kinases	208
12.3	Targeting NF- κ B activation	210

12.4	Targeting the MAPKs	217
12.5	Targeting PI3K	225
12.6	Further potential kinase targets	229
12.7	Conclusions	232
13	Pharmacokinetic/Pharmacodynamic Factors and Steroid Sensitivity	243
	<i>Gönther Hochhaus</i>	
13.1	Introduction	243
13.2	What factors are important for pulmonary efficacy and safety?	243
13.3	Pharmacodynamic aspects	246
13.4	Pharmacokinetic drug properties	247
13.5	Conclusion	257
14	Improved Lung Deposition: New Inhaler Devices	263
	<i>Omar S. Usmani</i>	
14.1	Introduction	263
14.2	Historical review of inhaled drug therapy	263
14.3	Deposition of aerosols within the respiratory tract	265
14.4	Assessing drug deposition in the lungs	268
14.5	Aerosol generation devices for inhaled drug therapy	271
	Index	283